Immutep Ltd (AU:IMM) has released an update.
Immutep Ltd reports promising results from a Phase II/III trial of its immunotherapy drug eftilagimod alpha (efti) in combination with paclitaxel for treating metastatic breast cancer, with a 50% overall response rate and a complete response in a patient who had been refractory to multiple therapies. The high-dose 90mg treatment, presented at ESMO Breast Cancer 2024 Congress, was well-tolerated with a favorable safety profile, and further data is expected in CY2024. The trial is part of the FDA’s Project Optimus initiative to optimize dosing for better efficacy and safety outcomes.
For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.
